FR2870698A1 - Sheet for use as e.g. mask for face, has composition and folding lines, where sheet is rolled up/folded back again from one line and parallel to prehension regions so that traction on regions in opposite directions allows sheet deployment - Google Patents

Abstract

The sheet has a composition on its side and an odd number of folding lines (A). The lines are parallel when the number is greater than 1. The sheet is folded around the lines such that one line is located on a side opposite to prehension regions (12, 13). The sheet is rolled up/folded back again from the line and parallel to the regions so that traction on the regions in opposite directions allows deployment of the sheet. An independent claim is also included for a process of fabrication of an article.

Description

The present invention relates to articles comprising a sheet

  intended to be applied to the human body, with a view to exerting a cosmetic or dermatological action on it. The expression human body must be understood in a broad sense and encompasses any region of skin, mucous membranes or integuments, and in particular the

face.

  No. 6,702,792 discloses a mask intended to be applied to the face. This mask is conditioned by being folded a first time on itself on the side of a first face, around a first fold line, and a second time on itself on the side of the opposite face, around a second fold line parallel to the first, the two fold lines being parallel to each other and arranged on either side of a center line passing through cutouts provided for the nose and mouth. The mask is then folded around a third fold line perpendicular to the first two. Tabs are provided on opposite edges of the mask to facilitate deployment of the mask by pulling on the tabs in opposite directions. The mask is introduced after being folded as above in a sachet and then impregnated with a lotion.

  Other masks are described in Japanese Patent Application JP 2000287751.

  There is a need to facilitate impregnation with a product to be applied to the body of a sheet introduced into a package after at least one folding step. There is also a need to reduce the cost of packaging.

  There is still a need to benefit from a sheet easy to set up on the area to be treated, avoiding a high number of manipulations thereof.

  The invention aims to meet at least one of these needs.

  According to one of its aspects, the subject of the invention is an article comprising: a sheet intended to be applied to the human body; a composition on at least one face of the sheet, this composition being intended to exert an action; on the human body, the article being characterized in that the sheet has two gripping regions substantially opposite each other when the sheet is unfolded and viewed from the front, in that the sheet comprises an odd number of primary fold lines substantially parallel to each other when this number is greater than one, the sheet being folded around this primary fold line or lines such that a primary fold line is located on the opposite side to said regions; for gripping, the sheet being wound or folded back on itself from the folding line situated on the side opposite to said gripping regions and substantially parallel to that in such a way that pulling on said gripping regions in opposite directions causes the sheet to expand.

  According to another of its aspects, the subject of the invention is also an article comprising: a sheet intended to be applied to the human body, a composition on at least one face of the sheet, this composition being intended to exert an action on the human body, the article being characterized in that the sheet is folded accordionally in more than two primary fold lines parallel to each other, so as to present to the user two gripping regions arranged such that a pulling in opposite directions on these gripping regions causes the sheet to expand.

  In both cases, the article allows easy and hygienic application of the sheet, avoiding the user having to perform many manipulations thereof to put it in place.

  The invention can further facilitate the impregnation of the sheet by the composition after the sheet has been introduced into a package such as for example a bag, in the folded state, by reducing the surface of the sheet in contact with the packaging with respect to a sheet which would be folded as described in US Patent 6,702,792.

  The invention further reduces the cost of conditioning the sheet by reducing the amount of packaging material needed to package the sheet, compared to a sheet that would be folded as described in US Patent 6,702,792.

  Advantageously, the sheet is a mask for the face, but the sheet may still be a mask for the bust or a wipe, for example.

  The sheet is preferably for single use.

  The aforementioned primary folding line or lines may extend parallel to a line joining cutouts for the eyes, or alternatively extend perpendicularly to this line.

  Preferably, when the primary fold line is single, this is a center line for the sheet. When the primary fold lines are more than one, one of them may be a centerline for the sheet and the others may be arranged symmetrically about that midline.

  The sheet may be completely impregnated with a liquid composition, advantageously comprising at least one cosmetic or dermatological active agent. This impregnation may have occurred after the folding of the sheet and its introduction into a package.

  The sheet may comprise any substrate compatible with the treatment to be performed, for example at least one layer of a nonwoven.

  The sheet may be packaged in an individual package, possibly after having been folded in two around a secondary fold line substantially perpendicular to the primary fold line (s), which makes it possible to further reduce its bulk. In this case, the sheet once extracted from its packaging must first be unfolded around this secondary fold line before the user pulls on the aforementioned gripping regions.

  The invention further relates to a method of manufacturing an article comprising a sheet intended to be applied to the human body, this method comprising the following steps, the sheet comprising two gripping regions substantially opposite one of the other when the sheet is unfolded and viewed from the front: - fold the sheet on itself around an odd number of primary fold lines, these primary fold lines being substantially parallel to each other when their number is greater than one the sheet being folded around this primary fold line (s) so that a primary fold line is on the opposite side to said grip regions, - wrapping or folding the sheet on itself from the line of primary folding located on the opposite side to said gripping regions, - conditioning the sheet in a corresponding packaging, preferably individual.

  The invention further relates to a method of manufacturing an article comprising a sheet intended to be applied to the human body, this method comprising the following steps: - folding accordion a sheet according to more than two parallel primary folding lines between they, so as to present to the user two gripping regions arranged so that a pull in opposite directions on these gripping regions causes the deployment of the sheet, conditioning the sheet in a corresponding package, preferably individual.

  If desired, the method may further include the step of folding the sheet around a secondary fold line, substantially perpendicular to the primary fold line (s), before introducing it into the package.

  The individual package may for example be a hermetic bag.

  The sheet may be impregnated with a composition intended to exert an action on the human body once introduced into the package and before closing it.

  The invention further relates, in another aspect, to a method for treating a region of the human body using an article as defined above.

  The invention will be better understood on reading the following detailed description of non-limiting examples thereof, and on examining the appended drawing, in which: FIGS. 1 to 3 illustrate various stages of preparing a sheet prior to being packaged in a package, in accordance with an exemplary embodiment of the invention; FIG. 4 schematically shows an example of an article containing the sheet thus prepared; and 6 illustrate the unfolding of the sheet, - Figures 7 to 9 illustrate another example of preparation of the sheet, - Figures 10 and 11 illustrate the deployment of the sheet thus prepared, - Figures 12 to 17 illustrate different stages of preparation of a sheet prior to its packaging in a package, according to another example of implementation of the invention, - figures 18 to 23 illustrate other preparation steps According to another embodiment of the invention, FIG. 24 illustrates the possibility of further folding the sheet before packaging, and FIG. schematically an example of an article containing the sheet of Figure 24.

  FIG. 1 shows a sheet 1 which, in the example under consideration, is in the form of a mask to be applied to the face, this sheet having an opening 2 for the mouth and cutouts 3 and 4 respectively for the eyes and the nose, and the periphery of the notches 5 facilitating the adaptation of the mask to the shape of the face. The outline of the sheet 1 is for example substantially oblong, as illustrated.

  The sheet 1 comprises a substrate which is impregnated entirely with a cosmetic or dermatological composition.

  This substrate may comprise or consist of a material capable of absorbing the composition and preferably also capable of partially releasing it.

  The substrate may for example comprise or consist of a non-water-soluble material, for example a non-woven material.

  The substrate may optionally have a composite structure, with different properties on each of its faces, for example.

  The composition used for the impregnation of the substrate contains, for example, a physiologically acceptable aqueous medium, that is to say compatible with the skin, the mucous membranes, the hair or the scalp.

  The cosmetic composition may contain, for example, between 10% and 99.9% water, and preferably between 30% and 90% water, by weight.

  The composition may be in any galenic form suitable for topical application, especially in the form of an aqueous or aqueous-alcoholic solution, of a homogeneous or two-phase lotion, of milk, of an aqueous or aqueous-alcoholic gel, of an emulsion obtained by dispersion of a fatty phase. in an aqueous phase (O / W) or vice versa (W / O), suspension, microemulsion, microcapsule, microparticle, or even vesicular dispersion of ionic type (liposomes) and / or nonionic.

  Particularly in the case of an emulsion, the fatty phase may be present in an amount of 0.5 to 80% by weight, and preferably 1 to 50% by weight, relative to the total weight of the composition.

  The oily phase or oily phase usually contains at least one oil.

  As oils that may be used in the composition, mention may be made, for example, of hydrocarbon-based oils of animal origin, such as perhydrosqualene, and hydrocarbon-based oils of vegetable origin, such as liquid triglycerides of fatty acids containing from 4 to 10 atoms. such as triglycerides of heptanoic or octanoic acids or, for example, sweet almond, sunflower, corn, soya, squash, grape seed, sesame, hazelnut, apricot, macadamia, arara, sunflower, castor oil, avocado, caprylic / capric acid triglycerides, such as those sold by the company Stearinerie Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba oil, shea butter oil, esters and synthetic ethers, in particular of fatty acids, such as the oils of formulas RICOOR2 and RIOR2 in which R1 represents the residue of a fatty acid containing from 8at 29 carbon atoms, and R2 represents a hydrocarbon chain, branched or unbranched, containing from 3 to 30 carbon atoms, for example purcellin oil, isononyl isononanoate, isopropyl myristate or palmitate. isopropyl, 2-ethylhexyl palmitate (or octyl palmitate), octyl-2-dodecyl stearate, octyl-2-dodecyl erucate, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrityl tetraisostearate, linear or branched hydrocarbons of mineral or synthetic origin, such as volatile or nonvolatile liquid paraffins, and derivatives thereof, petroleum jelly, polydecenes, hydrogenated polyisobutene, and the like; than parleam oil, - fatty alcohols having from 8 to 26 carbon atoms, such as cetyl alcohol, stearyl alcohol and their mixture (cetearyl alcohol), octyldodecanol, 2-butyloctanol, 2- hexyldecanol, 2undecylpentadecanol, oleic alcohol or linoleic alcohol, alkoxylated and especially ethoxylated fatty alcohols such as oleth-12 or ceteareth-20, partially fluorinated hydrocarbon oils and / or silicone oils such as those described in US Pat. JP-A-2-295912. As fluorinated oils, mention may also be made of perfluoromethylcyclopentane and perfluoro-1,3-dimethylcyclohexane, sold under the names FLUTEC PC1 and FLUTEC PC3 by BNFL Fluorochemicals; perfluoro-1,2-dimethylcyclobutane; perfluoroalkanes such as dodecafluoropentane and tetradecafluorohexane, sold under the names PF 5050 and PF 5060 by the company 3M, or the bromoperfluorooctyl sold under the name Foralkyl by the company Atochem; nonafluoromethoxybutane sold under the name MSX 4518 by the company 3M and nonafluoroethoxyisobutane; perfluoromorpholine derivatives, such as 4-trifluoromethyl perfluoromorpholine sold under the name PF 5052 by the company 3M, silicone oils such as volatile or non-volatile polymethylsiloxanes (PDMS) with a linear or cyclic silicone chain, liquid or pasty at room temperature , especially cyclopolydimethylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, during or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyltrimethicones, phenyldimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyldimethicones, diphenylmethyldiphenyltrisiloxanes, 2-phenylethyltrimethylsiloxysilicates, and polymethylphenylsiloxanes; their mixtures.

  By hydrocarbon oil is meant in the list of oils mentioned above, any oil predominantly comprising carbon and hydrogen atoms, and optionally ester, ether, fluoro, carboxylic acid and / or alcohol groups.

  In the case where the composition used is an emulsion, the oils, emulsifiers and coemulsifiers used may be chosen from those conventionally used in the cosmetic or dermatological field.

  The emulsifier and optionally the coemulsifier may be present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight, relative to the total weight of the composition. .

  The composition may contain ionic or nonionic emulsifiers, the choice of which depends on the desired emulsion (EM or H / E). It is possible to use as emulsifiers those usually used in the field under consideration.

  As emulsifiers, mention may be made, for example, of nonionic surfactants such as esters of fatty acids and polyols, and their oxyalkylenated and especially oxyethylenated derivatives; ethers of fatty alcohols and polyols, and their oxyalkylenated and especially oxyethylenated derivatives, and mixtures thereof. In the case of fatty acid esters and oxyalkylenated polyols or ethers of fatty alcohols and oxyalkylenated polyols, there may be, for example, from 1 to 150 oxyalkylenated and especially oxyethylenated groups. As emulsifiers, mention may be made more particularly of the mixture of glyceryl stearate and PEG-100 stearate, sold under the name Arlacel 165 by the company ICI; ethers of polyoxyethylenated fatty alcohols having from 1 to 100 oxyethylenated groups, for example ceteareth-12 and ceteareth-20, and mixtures containing them, such as the mixture sold under the name Emulgade CM by the company Henkel (a mixture of cetearyl isononanoate, ceteareth-20, cetearyl alcohol, glyceryl stearate, glycerin, ceteareth-12 and cetyl palmitate). The emulsifiers mentioned above are used for the preparation of O / W emulsions.

  It is also possible to add nonionic, anionic, amphoteric or zwitterionic surfactants to the composition of the invention, promoting the elimination of makeup and impurities, and which can make the composition foaming. It may be in particular foaming surfactants. As surfactants of this type, mention may be made, for example, of: (1) among the nonionic surfactants, the oxyethylenated oxypropylene block polymers such as Poloxamer 184 (CTFA name); alkylpolyglycosides and in particular alkylpolyglucosides (APG) having an alkyl group containing from 6 to 30 carbon atoms (alkyl-C6-C30 polyglucosides) and preferably 8 to 16 carbon atoms, for example decylglucoside (C9 / C11 alkyl). polyglucoside (1.4) such as the product sold under the name MYDOL 10 by the company Kao Chemicals, the product marketed under the name PLANTAREN 2000 UP or PLANTACARE 2000 UP by Henkel, and the product marketed under the name ORAMIX NS 10 by Seppic, caprylyl / capryl glucoside, such as the product sold under the name ORAMIX CG 110 by Seppic, laurylglucoside and the products marketed under the names PLANTAREN 1200 N and PLANTACARE 1200 by Henkel, and coco-glucoside as the product marketed under the name PLANTACARE 818 / UP by the company Henkel, (2) among the anionic surfactants, the alk ylsulfates, alkyl ether sulfates and their salts, especially their sodium salts, such as the mixture of Sodium Laureth Sulfate / Magnesium Laureth Sulfate / Sodium Laureth-8 Sulfate / Magnesium Laureth-8 Sulfate, sold under the name Texapon ASV by the company Henkel; sodium lauryl ether sulphate (C12-14 70/30) (2.2 OE) marketed under the names SIPON AOS 225 or TEXAPON N702 PATE by Henkel, ammonium lauryl ether sulphate (C12- 14 70/30) ) (30E) marketed under the name SIPON LEA 370 by Henkel; the ammonium (C12-C14) alkyl ether (90 E) ammonium sulphate sold under the name RHODAPEX AB / 20 by the company Rhodia Chimie, (3) among the amphoteric or zwitterionic surfactants, the alkylamido alkylamine derivatives such as N- N-di-sodium cocoyl-N-carboxymethoxyethyl-N-carboxymethylethylenediamine (CTFA name: Disodium cocoamphodiacetate) marketed in saline aqueous solution under the name MIRANOL C2M CONC NP by Rhodia Chimie; N-cocoyl-N-hydroxyethyl-N-carboxymethylethylenediamine N-sodium (CTFA name: sodium cocampho-acetate) and the mixture of coconut acid ethanolamides (CTFA name: Cocamide DEA).

  The composition may also comprise a mixture of these surfactants.

  The composition may contain, in addition to water, one or more solvents chosen from lower alcohols containing from 1 to 6 carbon atoms, such as ethanol; polyols such as glycerine; glycols such as butylene glycol, isoprene glycol, hexylene glycol, propylene glycol, polyethylene glycols such as PEG-8; sorbitol; sugars such as glucose, fructose, maltose, lactose, sucrose; and their mixtures.

  The composition used may furthermore comprise the adjuvants conventionally used in the fields under consideration, for example organic solvents, solubilizing agents, hydrophilic or lipophilic thickening and gelling agents, softeners, antioxidants, opacifiers, stabilizing agents , foaming agents, fillers, chelants, perfumes, filters, essential oils, dyestuffs, pigments, hydrophilic or lipophilic active agents, lipid vesicles optionally encapsulating one or more active ingredients, or any other ingredient normally used in cosmetics or dermatology.

  The composition may optionally also contain preservatives other than those mentioned above. The amounts of the various constituents are those conventionally used in the fields under consideration.

  As active agents, there may be mentioned, for example, without this list being limiting, the antiseborrhoeic active agents which make it possible to clean up the excess of sebum on the skin, and the antimicrobial agents which remove from the skin the microorganisms that may be present therein. , and their mixtures.

  Examples of antiseborrhoeic active agents that may be mentioned include sulfur and sulfur derivatives, benzoyl peroxide, zinc derivatives such as zinc sulphate and zinc oxide, aluminum chloride, selenium disulphide, B vitamins and in particular panthenol (vitamin B5) and niacinamide (vitamin B6 or PP), and mixtures thereof.

  As antimicrobials, there may be mentioned for example the following active ingredients: lactam, quinolone, ciprofloxacin, norfloxacin, tetracycline and its salts (hydrochloride), erythromycin and its salts (zinc, estolate, stearate), amikacine and its salts (sulfate ), 2,4,4'trichloro-2'-hydroxy diphenyl ether (triclosan), 3,4,4'-trichlorobanilide (tricarban), phenoxyethanol, phenoxypropanol, phenoxyisopropanol, doxycycline and its salts (hydrochloride), capreomycin and its salts (sulphate), chlorhexidine and its salts (gluconate, hydrochloride), chlorotetracycline and its salts (hydrochloride), oxytetracycline and its salts (hydrochloride), clindamycin and its salts (hydrochloride), ethambutol and its salts (hydrochloride), hexamidine and its salts (isethionate), metronidazole and its salts (hydrochloride), pentamidine and its salts (hydrochloride), gentamicin and its salts (sulfate), kanamycin and its salts (sulfate), linomycin and its salts (hydrochloride), methacycline and its salts (hydrochloride ), m thenamine and its salts (hippurate, mandelate), minocycline and its salts (hydrochloride), neomycin and its salts (sulphate), netilmicin and its salts (sulphate), paromomycin and its salts (sulphate), streptomycin and its salts (sulphate), tobramycin and its salts (sulphate), miconazole and its salts (hydrochloride), amanfadine and its salts (sulphate, hydrochloride), octopirox, parachlorometaxylenol, nystatin, tolnaftate, zinc pyrithione, clotrimazole, salicylic acid, n-octanoyl-5-salicylic acid ( or capryloylsalicylic acid), benzoyl peroxide, 3-hydroxybenzoic acid, glycolic acid, lactic acid, 4-hydroxybenzoic acid, acetylsalicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, phytic acid, N-acid - acetyl-L-cysteine, lipoic acid, azelaic acid, arachidonic acid, ibuprofen, naproxen, hydrocortisone, acetominophen, resorcinol, lidocaine hydrochloride, neocycine sulfate, octoxyglycerine, octanoylglycine (or caprylo) ylglycine), caprylylglycol (1,2-octanediol), 10-hydroxy-2-decanoic acid, and mixtures thereof. The preferred antimicrobial agents are 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, chlorhexidine and its salts, octopirox , zinc pyrithione, salicylic acid, 5-n-octanoyl salicylic acid, benzoyl peroxide, 3-hydroxybenzoic acid, glycolic acid, lactic acid, 4-hydroxybenzoic acid , acetylsalicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, phytic acid, N-acetyl-L-cysteine acid, lipoic acid, azelaic acid arachidonic acid, octoxyglycerine, octanoylglycine, caprylylglycol, 10-hydroxy-2-decanoic acid, and mixtures thereof.

  As hydrophilic gelling agents, mention may in particular be made of carboxyvinyl polymers such as carbomers; modified acrylic copolymers such as copolymers of acrylates / alkyl acrylates, such as the products sold under the names Pemulen by the company Goodrich; polyacrylamides, such as the product sold under the name Sepigel 305 by the company Seppic, or the poly (2-acrylamido-2-methylpropanesulphonic acid) marketed by the company Hoechst under the trademark Hostacerin AMPS (CTFA name: ammonium polyacryldimethyltauramide); polysaccharides, especially cellulose derivatives and natural gums such as xanthan gum or guar gum; and clays.

  As lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids, hydrophobic silica, polyethylenes, and mixtures thereof. Hydrophobic-functional polymers such as hydrophobic chain polysaccharides such as quaternized guar gums can also be used as gelling agents.

  The composition is prepared according to techniques well known to those skilled in the art.

  The composition is, for example, in the form of a PIT emulsion.

  This technique for obtaining O / W emulsion is, in principle, well known to those skilled in the art and is described in particular in the Phase Inversion Emusification articles, by Th. Forster et al., Published in Cosmetics & Toiletries, vol. 106, December 1991, pp. 49-52, Application of the phase-inversion-temperature method to the emulsification of cosmetics by T. MITSUI et al., Published in American Cosmetics and Perumery, Vol 87, December 1972.

  This technique makes it possible to obtain ultra-fine O / W emulsions, in which the average size of the globules constituting the fatty phase is within well-defined limits, namely between 50 and 1000 nm. These emulsions are extremely fluid and are particularly well suited for impregnating substrates insoluble in water to form cleaning articles or wipes.

  According to one particular embodiment, the PIT emulsion is prepared in concentrated form and then diluted, generally just before the impregnation, with one to nine parts of an aqueous phase that may also contain all or part of the previously dissolved preservatives. The viscosity of the composition used is, for example, between 100

  and 50000, preferably between 1000 and 10000 mPa.s and more preferably between 2000 and 5000 mPa.s. The viscosity is measured at room temperature (about 25 C) with a Brookfield DV apparatus.

  Referring now to FIGS. 2 and 3, the manner in which sheet 1 can be prepared for packaging in an individual package 10, which is shown diagrammatically in FIG. for example in the form of a bag for hermetic packaging of the sheet 1.

  This bag may for example comprise an impermeable film, possibly metallized, of rectangular shape folded on itself and thermo-sealed along three sides.

  FIG. 1 denotes by reference numerals 12 and 13 opposite gripping regions of the sheet. These regions 12 and 13 are adjacent to side edges 30 of the sheet in the illustrated example.

  In the example considered, we first fold the sheet 1 around a primary fold line A, as shown in Figure 2. This primary fold line A is substantially median, so that half of the sheet 1 is superimposed substantially on the other half.

  The sheet 1 thus folded on itself is then wound or folded on itself in the direction of the arrow B from the side 14 opposite the gripping regions 12 and 13, that is to say from the line of primary folding A and parallel to it, as illustrated in Figure 2, to result in the winding shown in Figure 3.

  The thus wound sheet is introduced into the package 10, by a small unsealed side thereof, then the impregnating composition is introduced into the package and the edge through which the composition was introduced is then sealed.

  In use, the user extracts the sheet 1 from the package 10, for example by tearing it with a notch constituting a tear initiation, then extracts the sheet 1 and is found with the rolled sheet as represented in FIG. 5, the gripping regions 12 and 13 being close to one another.

  The user can grasp the gripping regions 12 and 13 and move them apart to deploy the sheet, as shown in FIG.

  The user can apply the sheet 1 thus maintained on the face without having to seize it multiple times, and thus without unduly dirty it or his fingers.

  In the example just described, the primary fold line A is substantially perpendicular to the line Z joining the two cutouts 3 made for the eyes.

  In the variant embodiment illustrated in FIGS. 7 to 9, the primary fold line A is oriented substantially parallel to this line Z. In use, after taking out sheet 1 from its packaging, the user can enter two regions opposite grips 12 and 13 thereof, respectively adjacent to the lower and upper edges of the mask, as shown in FIG. 10, and deploying the sheet 1, as illustrated in FIG. 11.

  Figures 12 to 17 illustrate the possibility for the sheet 1 to be in a form other than a mask, for example a wipe.

  The primary folding line A may then for example correspond to a diagonal, as illustrated in FIG. 12. The gripping regions 12, 13 are adjacent to corners of the sheet in this example.

  Once the sheet has folded over itself around the primary fold line A, it can be folded back on itself in the direction of the arrow B from the opposite side 14 to the gripping regions 12, 13 as illustrated in FIGS. 13 to 17, each folding the sheet around fold lines D parallel to the primary folding line A. In a variant not shown, the sheet 1 is folded on itself on one side around two first lines primary folding folds located symmetrically on either side of a second primary fold line extending as that of Figure 12, and the sheet is folded in two on the opposite side around the latter primary fold line A. Then the sheet can be wound on itself from the opposite side to the gripping regions, i.e. from the first two primary fold lines.

  We will now describe with reference to Figures 18 to 23 the possibility of folding the sheet 1 accordion around more than two lines of primary folds, in this case five primary folding lines A parallel to each other in the example.

  These primary fold lines A are substantially equidistant, perpendicular to the line Z and divide the sheet 1 into six portions of substantially equal width, as can be seen in FIG.

  The user may, by pulling in opposite directions on the gripping regions 12 and 13, unfold the sheet 1 without further manipulation.

  As just seen, the sheet may be packaged in its package after at least one fold along a primary fold line, and then rolled or folded back on itself from the opposite side to the gripping regions.

  If necessary, the sheet may be further folded around a fold line C perpendicular to the primary fold line (s) A, as illustrated in FIG. 24.

  In this figure, the sheet of FIG. 9 is shown after folding around a secondary folding line C perpendicular to the primary folding line A. The sheet thus folded can be introduced into the bag 10 represented in FIG. less than that of Figure 4. The same could be done for the sheets of Figures 17 and 23.

  Of course, the invention is not limited to the embodiments which have just been described. In particular, the sheet may be shaped so as to allow it to be applied to a region of the body other than the face, for example the bust.

  Throughout the description, including the claims, the phrase having one must be understood to be synonymous with at least one, unless the opposite is specified.

Claims (17)

CLAIMS,   1. Article comprising: - a sheet (1) intended to be applied to the human body, - a composition on at least one side of the sheet, this composition being intended to exert an action on the human body, the article being characterized in that the sheet comprises two gripping regions (12, 13) substantially opposite one another when the sheet is deployed and viewed from the front, in that the sheet has an odd number of lines primary folds (A) substantially parallel to each other when this number is greater than one, the sheet being folded around this primary fold line or lines so that a primary fold line is located on the side (14) opposite to said gripping regions, the sheet being wound or folded back on itself from the primary fold line on the side (14) opposite to and substantially parallel to said gripping regions (12, 13), such that pulling on said gripping regions in opposite directions causes the sheet to expand.   2. Article comprising: - a sheet (1) intended to be applied to the human body; - a composition on at least one face of the sheet, this composition being intended to exert an action on the human body, the article being characterized in that the sheet is folded accordionally in more than two primary fold lines (A) parallel to each other so as to present to the user two gripping regions (12, 13) arranged such that a pulling in opposite directions on these gripping regions causes the sheet to expand.   3. Article according to claim 1 or 2, characterized in that the sheet is a mask for the face.   4. Article according to claim 1 or 2, characterized in that the primary fold line or lines (A) extend substantially parallel to a line (Z) joining cutouts (3) provided for the eyes.   5. Article according to claim 1 or 2, characterized in that the or the primary fold lines (A) extend substantially perpendicular to a line (Z) joining cutouts (3) provided for the eyes.   6. Article according to claim 1, characterized in that the sheet comprises a single primary fold line (A) which is substantially a center line for the sheet.   7. Article according to any one of the preceding claims, characterized in that the sheet (1) is completely impregnated with a liquid composition.   8. Article according to any one of the preceding claims, characterized in that the sheet (1) comprises at least one layer of a nonwoven.   9. Article according to any one of the preceding claims, characterized in that the sheet is packaged in an individual package (10).   10. Article according to claim 9, characterized in that the individual package (10) is a hermetic bag.   11. Article according to claim 9 or 10, characterized in that the sheet is packaged in the individual package by being folded in two around a secondary fold line (C) substantially perpendicular to the primary fold line (s). (AT).   12. Article according to any one of the preceding claims, characterized in that the gripping regions (12, 13) are adjacent to the edges of the sheet other than corners.   13. Article according to any one of claims 1 to 11, characterized in that the gripping regions (12, 13) are adjacent to corners of the sheet.   A method of manufacturing an article having a sheet for application to the human body, the method comprising the following steps, the sheet having two gripping regions (12, 13) substantially opposite one of the other when the sheet is unfolded and viewed from the front: - folding the sheet on itself around an odd number of primary fold lines (A), these primary fold lines being substantially parallel to each other when their number is greater to one, the sheet being folded around this primary fold line or lines such that a primary fold line is on the opposite side (14) to said gripping regions, - wrapping or folding the sheet on itself to from the primary folding line on the side opposite to said gripping regions, - conditioning the sheet in a packaging (10) corresponding, preferably individual.   15. A method of manufacturing an article comprising a sheet intended to be applied to the human body, this method comprising the following steps: - folding accordion a sheet according to more than two primary fold lines (A) parallel to each other, in such a way as to provide the user with two gripping regions (12, 13) arranged in such a way that traction in opposite directions on said gripping regions (12, 13) causes the sheet to unfold; a packaging (10) corresponding, preferably individual.   16. The method of claim 14 or 15, characterized in that it further comprises the step of folding the sheet around a secondary fold line (C) substantially perpendicular to the primary fold line (s). (AT).   17. Method according to one of claims 14 to 16, characterized in that the sheet is impregnated with a composition after being introduced into the package (10), and the latter is sealed.